Cogent Biosciences, Inc. (COGT) Stock

Cogent Biosciences, Inc. (COGT) is a Healthcare stock trading at $34.53 (as of 2026-06-18), with a market capitalization of $5.97B and a trailing P/E of -15.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cogent Biosciences, Inc. develops precision therapies for genetically defined diseases. Its lead candidate, CGT9486, is designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors, and it has a licensing agreement with Plexxikon for bezuclastinib.

Valuation — source: SEC EDGAR (first-party)
Price$34.53
Market Cap$5.97B
P/E Ratio-15.3
EV / EBITDA-15.7
Price / Book9.31
Price / Sales292.36
DCF Value (model)$-27.35
DCF Upside vs Price-179.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$14.69M
Net Margin-2239.3%
Return on Equity-58.3%
Debt / Equity0.37
Current Ratio15.14
Revenue Growth (YoY)-18.8%
EPS Growth (YoY)11.3%
FCF Growth (YoY)27.7%
Financial Health — source: SEC EDGAR
Altman Z-Score9.31 (safe)
Valuation vs Sector & Industry
Stock P/E-15.3
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-172.8%
vs Industry-188.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($889.99M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAndrew R. Robbins
Employees205
CountryUS
IPO Date2018-03-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Kymera Therapeutics, Inc. (KYMR)
  • PTC Therapeutics, Inc. (PTCT)
  • Vaxcyte, Inc. (PCVX)
  • Silexion Therapeutics Ltd. (SLXN)
  • Protagonist Therapeutics, Inc. (PTGX)
  • Apogee Therapeutics, Inc. (APGE)
  • Immunovant, Inc. (IMVT)
  • CRISPR Therapeutics AG (CRSP)
COGT earnings history · COGT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.